A New Era in Viral & Non-Viral Drug Product Manufacturing
With the manufacturing, packaging and quality control capabilities that you need available at scale, Emergent CDMO’s in-house drug product support services for clinical and commercial manufacturing help pave the way for your biotherapeutic or vaccine success. Flexible fill lines, single-use technologies, a large (and growing) production footprint, viral and non-viral platforms — an entire suite of capabilities from Emergent are ready to support your drug product manufacturing initiative. Plus, our size, adaptability, and expertise ideally position us to meet your needs as they evolve.
Our viral drug product manufacturing facility in Rockville, MD is home to the groninger® INTEGRA, a state-of-the-art high-speed fill/finish line. The INTEGRA offers integrated isolator technology and Biosafety Level 2 (BSL2) capabilities, in conjunction with an automated inspection, labeling, and packaging line, ideal for large scale fill/finish manufacturing of viral biotherapeutics and vaccines. The INTEGRA is an integral part of our strategic investment plan to support biopharma innovators in the fight against life-threatening viral diseases. Learn More
Vanrx Overview
The Vanrx SA25 Aseptic Filling Workcell is a state-of-the-art isolator fill line, providing our clients with a high level of sterility assurance and flexibility through an automated handling, filling, and closing process, designed to minimize line losses. If you have a high-value product and require a small-to-moderate batch size, the Vanrx may be the right fit for your program.
Learn more
groninger® FlexPro 50
The groninger® FlexPro 50, located at our Camden site in Baltimore, MD is a state-of-the-art filling suite, utilizing isolator-based technology for the aseptic processing of drug products in pre-sterilized ready-to-use (RTU) syringes, vials, and cartridges. An inline lyophilizer minimizes user intervention through an automated lyophilization loading system. The FlexPro 50 enhances Emergent CDMO's commitment to providing excellence in aseptic fill/finish to meet biopharmas’ diverse needs. Learn more
Development Services Center Overview
Our Development Services Center for Excellence in Gaithersburg, MD offers drug substance and drug product process development, analytical development, lab-scale manufacturing, and early-phase GMP release and stability testing. To learn more about Emergent CDMO's development services, take a 3D Virtual Tour of our Gaithersburg facility.
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
June 4th 2025Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
